Interpace Biosciences Adopts 2026 Equity Incentive Plan and ESPP

What Happened
Interpace Biosciences, Inc. (IDXG) filed an 8-K on August 26, 2026 reporting that at its annual meeting on August 20, 2026 stockholders approved the Company’s 2026 Equity Incentive Plan (the “2026 Incentive Plan”) and 2026 Employee Stock Purchase Plan (the “2026 ESPP”). The board had previously approved these plans subject to stockholder approval. The 2026 Incentive Plan replaces the Company’s 2019 Equity Incentive Plan and the 2026 ESPP replaces the Company’s 2019 Employee Stock Purchase Plan; no further awards or purchases will be made under the 2019 plans.

Key Details

• Stockholder approval occurred at the annual meeting on August 20, 2026; Form 8-K was filed August 26, 2026.
• The 2026 plans were described in the definitive proxy statement filed July 7, 2026; plan forms are incorporated by reference as Exhibits 10.1 and 10.2.
• Upon adoption, the 2019 Equity Incentive Plan and 2019 ESPP will no longer permit new grants or purchases.

Why It Matters
Adoption of the 2026 Incentive Plan and 2026 ESPP establishes the company’s current frameworks for equity awards and employee stock purchases going forward. For investors, the key implications are potential future equity grants and employee purchases under the new plans, which can affect share count and dilution over time. Investors should review the full plan terms (in the July 7, 2026 proxy and Exhibits 10.1/10.2) for specifics such as share allocations, award types, and limits to assess the potential dilution and executive/employee compensation mechanics.